TMCnet News
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceDURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Heat Biologics' presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021 at 7:00 AM Eastern Time. The webcast can be accessed here and on the investor relations section of Heat Biologics' website at https://ir.heatbio.com/. Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference. About Heat Biologics, Inc. For more information, please visit: www.heatbio.com, and also follow us on Twitter. Media and Investor Relations Contact |